Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes
Massimo Porta, Iiro Toppila, Niina Sandholm, S Mohsen Hosseini, Carol Forsblom, Kustaa Hietala, Lorenzo Borio, Valma Harjutsalo, Barbara E Klein, Ronald Klein, Andrew D Paterson, DCCT/EDIC Research Group, Per-Henrik Groop, FinnDiane Study Group, Massimo Porta, Iiro Toppila, Niina Sandholm, S Mohsen Hosseini, Carol Forsblom, Kustaa Hietala, Lorenzo Borio, Valma Harjutsalo, Barbara E Klein, Ronald Klein, Andrew D Paterson, DCCT/EDIC Research Group, Per-Henrik Groop, FinnDiane Study Group
Abstract
The risk of long-term diabetes complications is not fully explained by diabetes duration or long-term glycemic exposure, suggesting the involvement of genetic factors. Because thiamine regulates intracellular glucose metabolism and corrects for multiple damaging effects of high glucose, we hypothesized that variants in specific thiamine transporters are associated with risk of severe retinopathy and/or severe nephropathy because they modify an individual's ability to achieve sufficiently high intracellular thiamine levels. We tested 134 single nucleotide polymorphisms (SNPs) in two thiamine transporters (SLC19A2/3) and their transcription factors (SP1/2) for an association with severe retinopathy or nephropathy or their combination in the FinnDiane cohort. Subsequently, the results were examined for replication in the DCCT/EDIC and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) cohorts. We found two SNPs in strong linkage disequilibrium in the SLC19A3 locus associated with a reduced rate of severe retinopathy and the combined phenotype of severe retinopathy and end-stage renal disease. The association for the combined phenotype reached genome-wide significance in a meta-analysis that included the WESDR cohort. These findings suggest that genetic variations in SLC19A3 play an important role in the pathogenesis of severe diabetic retinopathy and nephropathy and may explain why some individuals with type 1 diabetes are less prone than others to develop microvascular complications.
Trial registration: ClinicalTrials.gov NCT00360815 NCT00360893.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4806664/bin/db151247f1.jpg)
Source: PubMed